Scarica il documento in formato pdf (556 KB) - ANCE

Frulla M, Mosena L, Tormena D, Piccioli
A, Simioni P, Girolami A. Residual
vein thrombosis as a predictive factor
of recurrent venous thromboembolism:
a prospective cohort study. Ann
Intern Med 2003 in press.
24. Cosmi B, Legnani C, Guazzaloca G,
Coccheri S, Palareti G. Residual vein
thrombosis and D-Dimer are independent
risk factors for recurrence after a
first episode of venous thromboembolism.
Pathophys Haemost Thromb 2002;
32 (suppl.2): 74
25. Hutten BA, Prins MH. Duration of
treatment with Vitamin K antagonist in
symptomatic venous thromboembolism.
The Cochrane Library 2000, Issue
3. Oxford: Update software
26. Agnelli G, Prandoni P, Santamaria MG
e al. Three months versus one year of
oral anticoagulant therapy for idiopatic
deep venous thrombosis. N Engl J
Med 2001; 345: 165-69
27. Ridker PM, Goldhaber SZ, Danielson E
et al. Long term, low-intensity Warfarin
therapy for the prevention of recurrent
venous thromboembolism. N Engl J
Med 2003, 348, n.15
28. Kearon C, Ginsberg JS, Kovacs MJ et al.
Comparison of low-intensity warfarin
therapy with conventional-intensity warfarin
therapy for long-term prevention
of recurrent Venous Thromboembolism.
N Engl J Med 2003; 349: 631-39
29. Van der Heijden JF, Hutten BA, Büller
HR, Prins MH. Vitamin K antagonist or
low-molecular-weight heparins for the
long-term treatment of symptomatic
venous thrombosis (Cochrane Review).
The Cochrane Library, Issue 3, 2002.
Oxford: Update Software
30. Cosmi B, Palareti G. Oral anticoagulant
therapy in venous thromboembolism.
Seminars in Vascular Medicine 2003,
in press.
31. Eriksson H, Wåhlander K, Gustafsson
D, Welin LT, Frison L, Schulman S, for
the Thrive Investigators. A randomized,
controlled, dose-guiding study of the
oral direct thrombin inhibitor ximelagatran
compared with standard therapy
for the treatment of acute deep vein
thrombosis: THRIVE I. J Thromb Haemost
2003; 1: 41-47
S. Coccheri
Venous Thromboembolism
35